Coherus Oncology
CHRS
106 hedge funds and large institutions have $576M invested in Coherus Oncology in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 54 increasing their positions, 21 reducing their positions, and 22 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 21
98% more call options, than puts
Call options by funds: $6.23M | Put options by funds: $3.15M
4.98% more ownership
Funds ownership: 73.3% → 78.28% (+5%)
3% less funds holding
Funds holding: 109 → 106 (-3)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
27% less capital invested
Capital invested by funds: $793M → $576M (-$217M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.8M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$9.44M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$7.97M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$6.5M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCG
JHL Capital Group
Chicago,
Illinois
|
-$14.8M |
| 2 |
Millennium Management
New York
|
-$12.8M |
| 3 |
PC
PointState Capital
New York
|
-$8.91M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$8.01M |
| 5 |
BM
Bridger Management
New York
|
-$6.97M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Simplex Trading
Chicago,
Illinois
| – | -$143K | -7,417 | Closed |
|
|
MAM
127
Meeder Asset Management
Dublin,
Ohio
| – | -$5K | -224 | Closed |
|
128
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$4K | -210 | Closed |
|
CHRS Hedge Fund Activity: Q2 2017 in Review
106 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2017, worth a combined $576M — down 27% from $793M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CHRS and 19 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 54 added.
The largest buyer was Wellington Management Group, adding an estimated $69.8M. The largest seller was JHL Capital Group, exiting entirely with an estimated $14.8M sold.
- 106 institutional investors held Coherus Oncology (CHRS) as of Q2 2017, down from 109 in Q1 2017.
- Funds reported $576M of Coherus Oncology stock for Q2 2017, down 27% quarter-over-quarter.
- 19 funds opened new Coherus Oncology positions in Q2 2017 and 22 closed out, a net change of -3 holders.
- The largest Coherus Oncology buyer in Q2 2017 was Wellington Management Group, an estimated $69.8M added.
- The largest Coherus Oncology seller in Q2 2017 was JHL Capital Group, an estimated $14.8M sold.
Based on aggregated 13F filings for Q2 2017.